114 related articles for article (PubMed ID: 38429887)
1. The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer.
Alfandari A; Moskovich D; Weisz A; Katzav A; Kidron D; Beiner M; Josephy D; Asali A; Hants Y; Yagur Y; Weitzner O; Ellis M; Itchaki G; Ashur-Fabian O
Mol Oncol; 2024 Mar; ():. PubMed ID: 38429887
[TBL] [Abstract][Full Text] [Related]
2. Restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system.
Popławski P; Wiśniewski JR; Rijntjes E; Richards K; Rybicka B; Köhrle J; Piekiełko-Witkowska A
PLoS One; 2017; 12(12):e0190179. PubMed ID: 29272308
[TBL] [Abstract][Full Text] [Related]
3. Disturbed expression of type 1 iodothyronine deiodinase splice variants in human renal cancer.
Piekielko-Witkowska A; Master A; Wojcicka A; Boguslawska J; Brozda I; Tanski Z; Nauman A
Thyroid; 2009 Oct; 19(10):1105-13. PubMed ID: 19534619
[TBL] [Abstract][Full Text] [Related]
4. Induction of type 1 iodothyronine deiodinase expression inhibits proliferation and migration of renal cancer cells.
Poplawski P; Rybicka B; Boguslawska J; Rodzik K; Visser TJ; Nauman A; Piekielko-Witkowska A
Mol Cell Endocrinol; 2017 Feb; 442():58-67. PubMed ID: 27940296
[TBL] [Abstract][Full Text] [Related]
5. DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.
Moskovich D; Alfandari A; Finkelshtein Y; Weisz A; Katzav A; Kidron D; Edelstein E; Veroslavski D; Perets R; Arbib N; Kadan Y; Fishman A; Lerer B; Ellis M; Ashur-Fabian O
Cancer Lett; 2021 Mar; 501():224-233. PubMed ID: 33221455
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte nuclear factor 4alpha contributes to thyroid hormone homeostasis by cooperatively regulating the type 1 iodothyronine deiodinase gene with GATA4 and Kruppel-like transcription factor 9.
Ohguchi H; Tanaka T; Uchida A; Magoori K; Kudo H; Kim I; Daigo K; Sakakibara I; Okamura M; Harigae H; Sasaki T; Osborne TF; Gonzalez FJ; Hamakubo T; Kodama T; Sakai J
Mol Cell Biol; 2008 Jun; 28(12):3917-31. PubMed ID: 18426912
[TBL] [Abstract][Full Text] [Related]
7. Human Type 1 Iodothyronine Deiodinase (
França MM; German A; Fernandes GW; Liao XH; Bianco AC; Refetoff S; Dumitrescu AM
Thyroid; 2021 Feb; 31(2):202-207. PubMed ID: 32718224
[No Abstract] [Full Text] [Related]
8. MiR-224 targets the 3'UTR of type 1 5'-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer.
Boguslawska J; Wojcicka A; Piekielko-Witkowska A; Master A; Nauman A
PLoS One; 2011; 6(9):e24541. PubMed ID: 21912701
[TBL] [Abstract][Full Text] [Related]
9. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
11. Short communication: quantitative comparison of iodothyronine deiodinase I and II mRNA expression in ovine tissues.
Foroughi MA; Dehghani H
Res Vet Sci; 2013 Dec; 95(3):891-3. PubMed ID: 23916591
[TBL] [Abstract][Full Text] [Related]
12. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
[TBL] [Abstract][Full Text] [Related]
13. Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
Moskovich D; Finkelshtein Y; Alfandari A; Rosemarin A; Lifschytz T; Weisz A; Mondal S; Ungati H; Katzav A; Kidron D; Mugesh G; Ellis M; Lerer B; Ashur-Fabian O
Oncogene; 2021 Nov; 40(44):6248-6257. PubMed ID: 34556811
[TBL] [Abstract][Full Text] [Related]
14. High T3, Low T4 Serum Levels in Mct8 Deficiency Are Not Caused by Increased Hepatic Conversion through Type I Deiodinase.
Wirth EK; Rijntjes E; Meyer F; Köhrle J; Schweizer U
Eur Thyroid J; 2015 Sep; 4(Suppl 1):87-91. PubMed ID: 26601078
[TBL] [Abstract][Full Text] [Related]
15. MiR-212-3p suppresses high-grade serous ovarian cancer progression by directly targeting MAP3K3.
Zhang L; Zhang Y; Wang S; Tao L; Pang L; Fu R; Fu Y; Liang W; Li F; Jia W
Am J Transl Res; 2020; 12(3):875-888. PubMed ID: 32269720
[TBL] [Abstract][Full Text] [Related]
16. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
17. Alternative splicing of iodothyronine deiodinases in pituitary adenomas. Regulation by oncoprotein SF2/ASF.
Piekielko-Witkowska A; Kedzierska H; Poplawski P; Wojcicka A; Rybicka B; Maksymowicz M; Grajkowska W; Matyja E; Mandat T; Bonicki W; Nauman P
Biochim Biophys Acta; 2013 Jun; 1832(6):763-72. PubMed ID: 23462647
[TBL] [Abstract][Full Text] [Related]
18. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
19. The identification of nuclear αvβ3 integrin in ovarian cancer: non-paradigmal localization with cancer promoting actions.
Seraya-Bareket C; Weisz A; Shinderman-Maman E; Teper-Roth S; Stamler D; Arbib N; Kadan Y; Fishman A; Kidron D; Edelstein E; Ellis M; Ashur-Fabian O
Oncogenesis; 2020 Jul; 9(7):69. PubMed ID: 32728020
[TBL] [Abstract][Full Text] [Related]
20. MiR-585-3p suppresses tumor proliferation and migration by directly targeting CAPN9 in high grade serous ovarian cancer.
Lu X; Li G; Liu S; Wang H; Chen B
J Ovarian Res; 2021 Jul; 14(1):90. PubMed ID: 34238324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
